Clinical Trial Update: Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI [Phase 2]

View source ↗

Summary

Phase 2 trial update on neridronate (Nerixia) for osteoporosis in patients with thalassemia major/intermedia showing efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Thalassemia Intermedia
• Thalassemia Major

Drugs mentioned

• Nerixia (neridronate)

Snippet

Sponsor: Ente Ospedaliero Ospedali Galliera | Conditions: Osteoporosis, Thalassemia Major | Phase 2 | Status: COMPLETED